Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

EVI1 (Ecotropic Viral Integration Site 1 (EVI1) and Myelodysplastic Syndrome 1 (MDS1)-EVI1)

Identity

Other namesPRDM3
HGNC (Hugo) EVI1
Location 3q26.2
Location_base_pair Starts at 170283981 and ends at 170346761 bp from pter ( according to hg18-Mar_2006)  [Mapping]

DNA/RNA

 
  Genomic locus of the human EVI1 gene and EVI1 mRNA variants. Asterisk, translation initiation codon; diamond, translation stop codon. (This figure was reprinted from Gene 396, R. Wieser, 'The oncogene and developmental regulator EVI1: Expression, biochemical properties, and biological functions', pages 346-357, Copyright Elsevier (2007), with permission from Elsevier. Gene homepage: http://www.sciencedirect.com/science/journal/03781119)
Description The human EVI1 gene spans approximately 65 kb of genomic DNA. 14 of its 16 exons are coding (Fig. 1A). Transcription can initiate from alternative exons 1a, 1b, 1c, 1d, or 3L (Fig. 1B), and several alternative splice variants of the EVI1 mRNA have been described (Delta324, -Rp9, Delta105; Fig. 1A).
The human MDS1 gene consists of 4 exons spread over a genomic region of more than 500 kb. MDS1 exon 4 is located less than 2 kb upstream of EVI1 exon1a. The MDS1-EVI1 mRNA presumably results from splicing of the second exon of MDS1 to the second exon of EVI1 (Fig. 1B).
Transcription Telomere to centromere.

Protein

 
  A) EVI1 and B) MDS1/EVI1 protein domains and EVI1 interacting proteins. Black boxes, zinc finger motifs; RD, repression domain, with binding motifs for the transcriptional corepressor CtBP depicted as black bars; ac, acidic region; PR, PR domain. This figure was reprinted from Gene 396, R. Wieser, 'The oncogene and developmental regulator EVI1: Expression, biochemical properties, and biological functions', pages 346-357, Copyright Elsevier (2007), with permission from Elsevier. Gene homepage: http://www.sciencedirect.com/science/journal/03781119.
Description Exon 3 of the human EVI1 gene contains two closely spaced ATG codons, either of which may serve as the translation initiation site. Depending on which ATG is used, proteins of 1051 or 1041 amino acids will be formed. EVI1 contains two domains of seven and three zinc finger motifs, respectively, a repression domain between the two sets of zinc fingers, and an acidic domain of unknown function at its C-terminus. It is a 145 kDa protein that is capable of binding to DNA in a sequence specific manner, and that interacts with transcriptional coactivators (P/CAF, CBP) and corepressors (CtBP, HDAC) as well as other sequence specific transcription factors (GATA1, Smad3).
Predicted translation of MDS1-EVI1 adds 188 amino acids to the N-terminus of EVI1. 63 of these additional amino acids are derived from the untranslated second exon and the untranslated part of the third exon of EVI1, and the remaining 125 from the MDS1 gene. MDS1-EVI1 contains a PR domain, which is about 40% homologous to the N-terminus of the retinoblastoma-binding protein, RIZ, and the PRDI-BF1 transcription factor. Some biological functions of MDS1/EVI1 are different from, or even antagonistic to, those of EVI1.
Expression In human tissues/organs, the EVI1 mRNA is expressed abundantly in kidney, lung, pancreas, stomach, ovaries, uterus, and prostate, to a lesser extent in the small intestine, colon, thymus, spleen, heart, brain, testis, and placenta, and at very low levels in skeletal muscle and bone marrow. The pattern of expression of MDS1-EVI1 is very similar to that of EVI1.
In the adult mouse, the Evi1 mRNA is expressed, at varying levels, in the kidney, lung, stomach, ovary, uterus, intestine, thymus, spleen, heart, brain, and liver. In the mouse embryo, Evi1 mRNA levels are high in the urinary system and Mullerian ducts, the lung, the heart, and the emerging limb buds.
Similar Evi1 expression patterns were also observed in Xenopus, chicken, and zebrafish.
Localisation Nuclear; in part in speckles.
Function Because of the spatially and temporally restricted expression of EVI1, it has been suggested that this gene plays an important role in development and could be involved in organogenesis, cell migration, cell growth, and differentiation.
In the mouse, homozygous disruption of the 6th exon of the Evi1 gene lead to embryonic lethality, with widespread hypocellularity, reduced body size, small or absent limb buds, a pale yolk sac and placenta, abnormal development of the nervous system and the heart, and massive haemorrhaging.
EVI1 is thought to exert its biological functions mainly by acting as a transcription factor. In addition, however, EVI1 has been reported to inhibit c-jun N-terminal kinase, and to stimulate PI3K/AKT signalling.
Homology EVI1 orthologs are present in many species. Evi1 proteins from other mammals share more than 90% amino acid sequence identity with the human protein, and Xenopus Evi1 is 77% identical to its human counterpart. MDS1-EVI1 shares an overall homology with the C. elegans Egl 43 protein that includes the PR domain at the N-terminus and the two zinc-finger domains. An MDS1/EVI1 ortholog, hamlet, is also present in Drosophila.

Implicated in

Entity t(3;3)(q21;q26) or inv(3)(q21q26)
Note 3q21q26 syndrome. Chromosomal rearrangements located either 5' or 3' of the EVI1 gene can activate its transcription in haematopoietic cells. Usually, t(3;3)(q21;q26) breakpoints are located 5' of EVI1, and inv(3)(q21q26) breakpoints 3' of it. Nevertheless, in both cases aberrant expression of the EVI1 gene may be due to its juxtaposition to the enhancer of the constitutively expressed housekeeping gene ribophorin 1 at 3q21.
Disease Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), and Chronic Myelogenous Leukemia (CML).
Prognosis Patients with EVI1 rearrangements have elevated platelet counts, marked hyperplasia with dysplasia of megakaryocytes, and a poor prognosis.
Cytogenetics Rearrangements at 3q26 may occur as a sole anomaly, but are often associated with monosomy 7 or deletion of the long arm of chromosome 7, and, less frequently, deletion in chromosome 5.
 
Normal and leukemia-associated EVI1 protein variants.
Oncogenesis Inappropriate expression of EVI1 in haematopoietic cells alters differentiation into granulocytes, erythrocytes and megakaryocytes. EVI1 promotes the proliferation of certain cell types, but inhibits the growth of others. It interferes with growth inhibition by TGF-b and with apoptosis elicited by a variety of stimuli. In a murine bone marrow transduction/transplantation model, EVI1 caused a disease resembling human myelodysplastic syndrome. Additional coexpression of Hoxa9 and Meis 1 lead to overt leukemia.
  
Entity t(3;21)(q26;q22)
Disease Therapy-related MDS/AML and CML during the blast crisis.
Prognosis Poor.
Cytogenetics Complex.
Abnormal Protein AML1 -MDS1-EVI1
Oncogenesis AML1-MDS1-EVI1 is a chimeric transcription factor that interferes with AML1 functions in a dominant negative manner, but shares some biological effects with EVI1.
  
Entity t(3;12)(q26;p13)
Disease CML during the blast crisis and MDS in transformation.
Prognosis Poor.
Cytogenetics Complex.
Abnormal Protein Overexpression of a fusion protein between the amino terminus of TEL, which does not contain any functional domains, and the entire MDS1/EVI1 protein is driven by the TEL promoter.
  
Entity AML without 3q26 rearrangements.
Note EVI1 may also be overexpressed in AML, MDS, or CML in blast crisis in the absence of any cytogenetically detectable 3q26 rearrangements.
Disease AML, MDS, CML.
Prognosis Poor (AML).
Oncogenesis as above.
  

Breakpoints

 
Note Other chromosomal rearrangements that results in the inappropriate expression of EVI1 include t(2;3)(p13;q26), t(2;3)(q23;q26), t(3;7)(q27;q22), t(3;8)(q26;q24), t(3;13)(q26;q13-14), and t(3;17)(q26;q22).

External links

Nomenclature
HGNC (Hugo)EVI1   3498
Entrez_Gene (NCBI)EVI1  2122  ecotropic viral integration site 1
Cards
AtlasEVI103q26ID19
GeneCards (Weizmann)EVI1
Ensembl (Hinxton)ENSG00000085276 [Gene_View]  EVI1 [Vega]
AceView (NCBI)EVI1
Genatlas (Paris)EVI1
euGene (Indiana)2122
SOURCE (Stanford)NM_001105077 NM_001105078 NM_005241
Genomic and cartography
GoldenPath (UCSC)EVI1  -  3q26.2   chr3:170283981-170346761 -  3q26   [Description]    (hg18-Mar_2006)
EnsemblEVI1 - 3q26 [CytoView]
Mapping of homologs : NCBIEVI1 [Mapview]
OMIM165215   
Gene and transcription
Gene : Genbank (Entrez)AA043944 AF164155 AF164156 AF164157 AF487422
Reference sequence (RefSeq transcript) :SRSNM_001105077 NM_001105078 NM_005241
Reference transcript : EntrezNM_001105077 NM_001105078 NM_005241
RefSeq genomic : SRSAC_000046 AC_000135 NC_000003 NT_005612 NW_001838884 NW_921807
RefSeq genomic : EntrezAC_000046 AC_000135 NC_000003 NT_005612 NW_001838884 NW_921807
Consensus coding sequences : CCDS NCBIEVI1
Cluster EST : UnigeneHs.656395 [ SRS ] Hs.656395 [ NCBI ]
Alternative Splicing : Fast-db (Paris)14505
Protein : pattern, domain, 3D structure
Protein : UniProt/SwissProtQ03112 (SRS) Q03112 (Expasy) Q03112 (Uniprot)
With graphics : InterProQ03112
Splice isoforms : VarSplice FASTAQ03112(VarSplice FASTA)
Domaine pattern : Prosite (SRS)ZINC_FINGER_C2H2_1 (PS00028)    ZINC_FINGER_C2H2_2 (PS50157)   
Domain pattern : Prosite (Expaxy)ZINC_FINGER_C2H2_1 (PS00028)    ZINC_FINGER_C2H2_2 (PS50157)   
Domains : Interpro (SRS)Znf_C2H2    Znf_C2H2-like    Znf_C2H2/integrase_DNA-bd   
Domains : Interpro (EBI)Znf_C2H2    Znf_C2H2-like    Znf_C2H2/integrase_DNA-bd   
Related proteins : CluSTrQ03112
Domain families : Pfam SRSzf-C2H2 (PF00096)   
Domain families : Pfam Sangerzf-C2H2 (PF00096)   
Domain families : Pfam NCBIpfam00096   
Domain families : Smart EMBLZnF_C2H2 (SM00355)
Domain structure : Prodom (Prabi Lyon)Znf_C2H2 (PD000003)   
Blocks (Seattle)Q03112
Crystal structure of protein : PDB SRS
Crystal structure of protein : PDBSum
Crystal structure of protein : IMB
Crystal structure of protein : PDB RSDB
HPRD01310
Protein Interaction databases
DIP (DOE-UCLA)Q03112
IntAct (EBI)Q03112
Polymorphism : SNP, mutations, diseases
Single Nucleotide Polymorphism (SNP) : dbSNP NCBIEVI1
SNP : GeneSNP UtahEVI1
SNP : HGBaseEVI1
Genetic variants : HAPMAPEVI1
Somatic Mutations in Cancer : COSMICEVI1 
Translocation Breakpoints in Cancer : TICdbEVI1 
Mutations and Diseases : HGMDEVI1
Hereditary diseases : OMIM165215   
Hereditary diseases : GENETests165215   
Diseases : Genetic AssociationEVI1
General knowledge
Homologs : HomoloGeneEVI1
Homology/Alignments : Family Browser UCSCEVI1
Phylogenetic Trees/Animal Genes : TreeFamEVI1
Chemical/Protein Interactions : CTD2122
Keywords Ontology : AmiGOmolecular_function  DNA binding  protein binding  intracellular  nucleus  multicellular organismal development  biological_process  zinc ion binding  metal ion binding  
Keywords Ontology : EGO-EBImolecular_function  DNA binding  protein binding  intracellular  nucleus  multicellular organismal development  biological_process  zinc ion binding  metal ion binding  
Pathways : BIOCARTA
Pathways : KEGGMAPK signaling pathway
Other databases
Probes
Probes : ImagenesEVI1 Related clones (RZPD - Berlin)
Literature
PubMed36 Pubmed reference(s) in Entrez
PubGeneEVI1

Bibliography

Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines.
Morishita K, Parker DS, Mucenski ML, Jenkins NA, Copeland NG, Ihle JN
Cell. 1988 ; 54 (6) : 831-840.
PMID 2842066
 
Alternative splicing of the Evi-1 zinc finger gene generates mRNAs which differ by the number of zinc finger motifs.
Bordereaux D, Fichelson S, Tambourin P, Gisselbrecht S
Oncogene. 1990 ; 5 (6) : 925-927.
PMID 2113669
 
Unique expression of the human Evi-1 gene in an endometrial carcinoma cell line: sequence of cDNAs and structure of alternatively spliced transcripts.
Morishita K, Parganas E, Douglass EC, Ihle JN
Oncogene. 1990 ; 5 (7) : 963-971.
PMID 2115646
 
Patterns of Evi-1 expression in embryonic and adult tissues suggest that Evi-1 plays an important regulatory role in mouse development.
Perkins AS, Mercer JA, Jenkins NA, Copeland NG
Development (Cambridge, England). 1991 ; 111 (2) : 479-487.
PMID 1893871
 
Involvement of the AML1 gene in the t(3;21) in therapy-related leukemia and in chronic myeloid leukemia in blast crisis.
Nucifora G, Birn DJ, Espinosa R 3rd, Erickson P, LeBeau MM, Roulston D, McKeithan TW, Drabkin H, Rowley JD
Blood. 1993 ; 81 (10) : 2728-2734.
PMID 8490181
 
Induction of two alternatively spliced evi-1 proto-oncogene transcripts by cAMP in kidney cells.
Bartholomew C, Clark AM
Oncogene. 1994 ; 9 (3) : 939-942.
PMID 8108138
 
Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia.
Mitani K, Ogawa S, Tanaka T, Miyoshi H, Kurokawa M, Mano H, Yazaki Y, Ohki M, Hirai H
The EMBO journal. 1994 ; 13 (3) : 504-510.
PMID 8313895
 
Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3;21)(q26;q22) translocations.
Nucifora G, Begy CR, Kobayashi H, Roulston D, Claxton D, Pedersen-Bjergaard J, Parganas E, Ihle JN, Rowley JD
Proceedings of the National Academy of Sciences of the United States of America. 1994 ; 91 (9) : 4004-4008.
PMID 8171026
 
Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations.
Russell M, List A, Greenberg P, Woodward S, Glinsmann B, Parganas E, Ihle J, Taetle R
Blood. 1994 ; 84 (4) : 1243-1248.
PMID 8049440
 
Identification of a breakpoint cluster region 3' of the ribophorin I gene at 3q21 associated with the transcriptional activation of the EVI1 gene in acute myelogenous leukemias with inv(3)(q21q26).
Suzukawa K, Parganas E, Gajjar A, Abe T, Takahashi S, Tani K, Asano S, Asou H, Kamada N, Yokota J
Blood. 1994 ; 84 (8) : 2681-2688.
PMID 7919381
 
t(2;3)(p23;q26) in a patient with AML M2.
Levaltier X, Penther D, Bastard C, Troussard X
British journal of haematology. 1996 ; 92 (4) : page 1027.
PMID 8616064
 
Fluorescence in situ hybridization analysis of t(3; 12)(q26; p13): a recurring chromosomal abnormality involving the TEL gene (ETV6) in myelodysplastic syndromes.
Raynaud SD, Baens M, Grosgeorge J, Rodgers K, Reid CD, Dainton M, Dyer M, Fuzibet JG, Gratecos N, Taillan B, Ayraud N, Marynen P
Blood. 1996 ; 88 (2) : 682-689.
PMID 8695816
 
Expression of EVI1 and the Retinoblastoma genes in acute myelogenous leukemia with t(3;13)(q26;q13-14).
Yufu Y, Sadamura S, Ishikura H, Abe Y, Katsuno M, Nishimura J, Nawata H
American journal of hematology. 1996 ; 53 (1) : 30-34.
PMID 8813093
 
The Evi1 proto-oncogene is required at midgestation for neural, heart, and paraxial mesenchyme development.
Hoyt PR, Bartholomew C, Davis AJ, Yutzey K, Gamer LW, Potter SS, Ihle JN, Mucenski ML
Mechanisms of development. 1997 ; 65 (1-2) : 55-70.
PMID 9256345
 
The EVI1 gene in myeloid leukemia.
Nucifora G
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 1997 ; 11 (12) : 2022-2031.
PMID 9447815
 
Fusion of ETV6 to MDS1/EVI1 as a result of t(3;12)(q26;p13) in myeloproliferative disorders.
Peeters P, Wlodarska I, Baens M, Criel A, Selleslag D, Hagemeijer A, Van den Berghe H, Marynen P
Cancer research. 1997 ; 57 (4) : 564-569.
PMID 9044825
 
The EVI-1 gene--its role in pathogenesis of human leukemias.
Jkowska J, Witt M
Leukemia research. 2000 ; 24 (7) : 553-558.
PMID 10867128
 
The evi-1 oncoprotein inhibits c-Jun N-terminal kinase and prevents stress-induced cell death.
Kurokawa M, Mitani K, Yamagata T, Takahashi T, Izutsu K, Ogawa S, Moriguchi T, Nishida E, Yazaki Y, Hirai H
The EMBO journal. 2000 ; 19 (12) : 2958-2968.
PMID 10856240
 
Interaction of EVI1 with cAMP-responsive element-binding protein-binding protein (CBP) and p300/CBP-associated factor (P/CAF) results in reversible acetylation of EVI1 and in co-localization in nuclear speckles.
Chakraborty S, Senyuk V, Sitailo S, Chi Y, Nucifora G
The Journal of biological chemistry. 2001 ; 276 (48) : 44936-44943.
PMID 11568182
 
High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients.
Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL, Valk PJ, van der Poel-van de Luytgaarde S, Hack R, Slater R, Smit EM, Beverloo HB, Verhoef G, Verdonck LF, Ossenkoppele GJ, Sonneveld P, de Greef GE, Lwenberg B, Delwel R
Blood. 2003 ; 101 (3) : 837-845.
PMID 12393383
 
Acute myelogenous leukemia with the t(3;12)(q26;p13) translocation: case report and review of the literature.
Voutsadakis IA, Maillard N
American journal of hematology. 2003 ; 72 (2) : 135-137.
PMID 12555218
 
Quantitative comparison of the expression of EVI1 and its presumptive antagonist, MDS1/EVI1, in patients with myeloid leukemia.
Vinatzer U, Mannhalter C, Mitterbauer M, Gruener H, Greinix H, Schmidt HH, Fonatsch C, Wieser R
Genes, chromosomes & cancer. 2003 ; 36 (1) : 80-89.
PMID 12461752
 
Interphase fluorescence in situ hybridization assay for the detection of rearrangements of the EVI-1 locus in chromosome band 3q26 in myeloid malignancies.
Wieser R, Schreiner U, Rieder H, Pirc-Danoewinata H, Grner H, Loncarevic IF, Fonatsch C
Haematologica. 2003 ; 88 (1) : 25-30.
PMID 12551823
 
EVI1 induces myelodysplastic syndrome in mice.
Buonamici S, Li D, Chi Y, Zhao R, Wang X, Brace L, Ni H, Saunthararajah Y, Nucifora G
The Journal of clinical investigation. 2004 ; 114 (5) : 713-719.
PMID 15343390
 
Translocation t(2;3)(p15-23;q26-27) in myeloid malignancies: report of 21 new cases, clinical, cytogenetic and molecular genetic features.
Stevens-Kroef M, Poppe B, van Zelderen-Bhola S, van den Berg E, van der Blij-Philipsen M, Geurts van Kessel A, Slater R, Hamers G, Michaux L, Speleman F, Hagemeijer A
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2004 ; 18 (6) : 1108-1114.
PMID 15085164
 
Regulation of the expression of the oncogene EVI1 through the use of alternative mRNA 5'-ends.
Aytekin M, Vinatzer U, Musteanu M, Raynaud S, Wieser R
Gene. 2005 ; 356 : 160-168.
PMID 16014322
 
Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells.
Du Y, Jenkins NA, Copeland NG
Blood. 2005 ; 106 (12) : 3932-3939.
PMID 16109773
 
The Evi1 proto-oncoprotein blocks endomitosis in megakaryocytes by inhibiting sustained cyclin-dependent kinase 2 catalytic activity.
Kilbey A, Alzuherri H, McColl J, Cals C, Frampton J, Bartholomew C
British journal of haematology. 2005 ; 130 (6) : 902-911.
PMID 16156860
 
Evi-1 expression in Xenopus.
Mead PE, Parganas E, Ohtsuka S, Morishita K, Gamer L, Kuliyev E, Wright CV, Ihle JN
Gene expression patterns : GEP. 2005 ; 5 (5) : 601-608.
PMID 15905132
 
Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression.
Yuasa H, Oike Y, Iwama A, Nishikata I, Sugiyama D, Perkins A, Mucenski ML, Suda T, Morishita K
The EMBO journal. 2005 ; 24 (11) : 1976-1987.
PMID 15889140
 
Conservation and expression of a novel alternatively spliced Evi1 exon.
Alzuherri H, McGilvray R, Kilbey A, Bartholomew C
Gene. 2006 ; 384 : 154-162.
PMID 17014970
 
Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.
Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, Glimm H, Khlcke K, Schilz A, Kunkel H, Naundorf S, Brinkmann A, Deichmann A, Fischer M, Ball C, Pilz I, Dunbar C, Du Y, Jenkins NA, Copeland NG, Lthi U, Hassan M, Thrasher AJ, Hoelzer D, von Kalle C, Seger R, Grez M
Nature medicine. 2006 ; 12 (4) : 401-409.
PMID 16582916
 
EVI1 is consistently expressed as principal transcript in common and rare recurrent 3q26 rearrangements.
Poppe B, Dastugue N, Vandesompele J, Cauwelier B, De Smet B, Yigit N, De Paepe A, Cervera J, Recher C, De Mas V, Hagemeijer A, Speleman F
Genes, chromosomes & cancer. 2006 ; 45 (4) : 349-356.
PMID 16342172
 
Evi1 is specifically expressed in the distal tubule and duct of the Xenopus pronephros and plays a role in its formation.
Van Campenhout C, Nichane M, Antoniou A, Pendeville H, Bronchain OJ, Marine JC, Mazabraud A, Voz ML, Bellefroid EJ
Developmental biology. 2006 ; 294 (1) : 203-219.
PMID 16574097
 
t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy.
Yin CC, Cortes J, Barkoh B, Hayes K, Kantarjian H, Jones D
Cancer. 2006 ; 106 (8) : 1730-1738.
PMID 16532439
 
An interphase fluorescence in situ hybridisation assay for the detection of 3q26.2/EVI1 rearrangements in myeloid malignancies.
Bobadilla D, Enriquez EL, Alvarez G, Gaytan P, Smith D, Slovak ML
British journal of haematology. 2007 ; 136 (6) : 806-813.
PMID 17341266
 
Trib1 and Evi1 cooperate with Hoxa and Meis1 in myeloid leukemogenesis.
Jin G, Yamazaki Y, Takuwa M, Takahara T, Kaneko K, Kuwata T, Miyata S, Nakamura T
Blood. 2007 ; 109 (9) : 3998-4005.
PMID 17227832
 
The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions.
Wieser R
Gene. 2007 ; 396 (2) : 346-357.
PMID 17507183
 
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

Contributor(s)

Written05-2003Soumen Chakraborty, Silvia Buonamici, Vitalyi Senyuk, Giuseppina Nucifora
Dept. of Pathology(Rm.3314), Molecular Biology and Research Building University Of Illinois At Chicago 900 South Ashland Avenue Chicago, IL-60607, USA
Updated12-2007Rotraud Wieser
Medizinische Universitaet Wien, Department fuer Medizinische Genetik, Waehringerstr. 10, A-1090 Wien, Austria

Citation

This paper should be referenced as such :
Chakraborty S, Buonamici S, Senyuk V, Nucifora G . EVI1 (Ecotropic Viral Integration Site 1 (EVI1) and Myelodysplastic Syndrome 1 (MDS1)-EVI1). Atlas Genet Cytogenet Oncol Haematol. May 2003 .
URL : http://AtlasGeneticsOncology.org/Genes/EVI103q26ID19.html
Wieser R . EVI1 (Ecotropic Viral Integration Site 1 (EVI1) and Myelodysplastic Syndrome 1 (MDS1)-EVI1). Atlas Genet Cytogenet Oncol Haematol. December 2007 .
URL : http://AtlasGeneticsOncology.org/Genes/EVI103q26ID19.html

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Sat Jun 27 16:41:20 CEST 2009

Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.